Patel Chintu 4
4 · Amneal Pharmaceuticals, Inc. · Filed Mar 3, 2026
Research Summary
AI-generated summary of this filing
Amneal (AMRX) Co-CEO Chintu Patel Receives Equity Award
What Happened
Chintu Patel, Co‑CEO and director of Amneal Pharmaceuticals (AMRX), received two equity awards on March 2, 2026: 190,632 restricted stock units (RSUs) and 354,031 performance‑based RSUs. The grants are reported as derivative awards (acquired at $0.00 in the Form 4) — the 190,632 are time‑based RSUs and the 354,031 are performance RSUs (the filing reports the maximum number issuable).
Key Details
- Transaction date: March 2, 2026; Form 4 filed March 3, 2026 (timely).
- Reported grant amounts: 190,632 time‑based RSUs and 354,031 performance RSUs; both shown at $0.00 acquisition price (derivative awards).
- Shares owned after transaction: Not specified in the provided filing.
- Vesting: Time‑based RSUs vest in four equal annual installments beginning March 2, 2027. Performance RSUs vest (if earned) in full on February 28, 2029.
- Performance payout: Performance RSUs pay out based on average closing‑price targets at the end of the three‑year performance period; payout may range from 0% to 200% of the target award. The 354,031 figure represents the maximum possible shares issuable.
- Footnotes: Each RSU equals one contingent right to receive one Class A common share upon vesting.
Context
These are grants of restricted stock units — no shares were delivered immediately. Time‑based RSUs signal expected future compensation and align management with shareholders over the vesting period; performance RSUs are contingent on stock price targets and can yield anywhere from 0% to 200% of target shares. Awards are common executive compensation and do not represent an open‑market purchase or sale.
Insider Transaction Report
- Award
Restricted Stock Units
[F1][F2]2026-03-02+190,632→ 190,632 total→ Class A Common Stock (190,632 underlying) - Award
Performance-Based Restricted Stock Units
[F3][F4]2026-03-02+354,031→ 354,031 total→ Class A Common Stock (354,031 underlying)
Footnotes (4)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
- [F2]The restricted stock units vest in four equal annual installments beginning on March 2, 2027.
- [F3]Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
- [F4]Represents a performance-based restricted stock unit grant of 354,031 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period.